J&J’s Tecvayli-Darzalex Faspro combination approved for myeloma after MajesTEC-3 Phase 3 results
FDA approves J&J’s teclistamab plus daratumumab for relapsed myeloma from second line. Analyse the MajesTEC-3 data, safety profile, and what this changes for treatment.